Best Antibiotic Choice for Aerococcus urinae UTI Without Sensitivities
For Aerococcus urinae urinary tract infection when sensitivities are not available, nitrofurantoin is the recommended first-line treatment option due to its demonstrated clinical and microbiological efficacy.
Understanding Aerococcus urinae
Aerococcus urinae is an emerging uropathogen that is increasingly recognized as a cause of urinary tract infections, particularly in:
- Older adults
- Patients with multimorbidity
- Those with urologic conditions or chronic urinary retention
- Patients with indwelling catheters
Treatment Recommendations
First-line options:
Nitrofurantoin
Penicillins/Ampicillin
- Excellent in vitro activity against A. urinae (100% susceptibility) 2
- Appropriate for patients who cannot tolerate nitrofurantoin
Alternative options:
Fosfomycin
- Dosage: 3 g single-dose sachet
- Consider for uncomplicated lower UTI
- Recommended as a first-line agent for uncomplicated UTIs 3
Pivmecillinam
- Has shown success in treating A. urinae cystitis 1
- May be considered if other options are unavailable
For complicated UTI or pyelonephritis:
Fluoroquinolones (e.g., Ciprofloxacin)
Ceftriaxone
- For severe infections requiring parenteral therapy
- Dosage: 1-2 g IV daily 3
Treatment Duration
- For uncomplicated cystitis: 5-7 days 3
- For complicated UTI: 7-14 days 3
- For pyelonephritis: 7-14 days 3
Important Considerations
- Obtain urine culture before initiating therapy whenever possible 3
- A. urinae may be misidentified by some commercial detection systems 4
- If the patient has an indwelling catheter that has been in place for >2 weeks, consider catheter replacement before initiating antimicrobial therapy 3
- Monitor for clinical response within 48-72 hours
- A. urinae can occasionally cause serious complications such as bacteremia and endocarditis, particularly in elderly males with predisposing conditions 4
Common Pitfalls to Avoid
Using sulfonamides: A. urinae is typically resistant to sulfonamides, making trimethoprim-sulfamethoxazole potentially ineffective 4
Relying on fluoroquinolones as first-line therapy: Despite their broad spectrum, fluoroquinolones should be reserved for more severe infections due to increasing resistance and risk of collateral damage 3
Inadequate treatment duration: Too short a course may lead to treatment failure and recurrence
Failure to recognize the organism: A. urinae may be misidentified as alpha-hemolytic streptococci or staphylococci in routine cultures
Missing complicated infections: A. urinae can cause invasive infections, so patients with persistent symptoms despite appropriate therapy should be evaluated for complications
By following these recommendations, clinicians can effectively treat Aerococcus urinae UTIs even when antimicrobial susceptibility testing is not immediately available.